Ameriprise
CERE

Ameriprise’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Ameriprise’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,347,680
Closed -$55.1M – 4050
2024
Q2 		$55.1M Buy
1,347,680
+784,907
+139% +$32.7M 0.01% 756
2024
Q1 		$23.8M Buy
562,773
+557,340
+10,258% +$23.4M 0.01% 1200
2023
Q4 		$230K Buy
+5,433
New +$156K ﹤0.01% 3687

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Ameriprise's CERE Position: Q3 2024 in Review

Ameriprise sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,347,680 shares — an estimated $55.1M sold.

Ameriprise first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $55.1M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Ameriprise reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Ameriprise sold 1,347,680 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $55.1M.
  • Ameriprise first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Ameriprise's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $55.1M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Ameriprise's 13F filing for Q3 2024, filed 14 Nov 2024.